APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Human Coagulation Factor IX

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recombinant Human Coagulation Factor IX Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174031480323 December 2025190 pages

Choose your research edition.

Industry ResearchRecombinant Human Coagulation Factor IX Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Human Coagulation Factor IX Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Recombinant Human Coagulation Factor IX Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Human Coagulation Factor IX Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Human Coagulation Factor IX Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Recombinant Human Coagulation Factor IX market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Recombinant Human Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Human Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Human Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recombinant Human Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Human Coagulation Factor IX include Bio-Techne, Cayman, Cusabio, Grifols, IDELVION, NovoPro Bioscience, Octapharma, Sino Biological and Baxter, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Human Coagulation Factor IX market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Human Coagulation Factor IX and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Human Coagulation Factor IX sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Human Coagulation Factor IX market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Human Coagulation Factor IX Segment by Company

Bio-Techne

Cayman

Cusabio

Grifols

IDELVION

NovoPro Bioscience

Octapharma

Sino Biological

Baxter

Biogen

Diagbio

Hualan Bio

Sanofi

ChinaBiologic

Shuyang

Recombinant Human Coagulation Factor IX Segment by Type

500 IU/Bottle

250 IU/Bottle

2000 IU/Bottle

1000 IU/Bottle

Recombinant Human Coagulation Factor IX Segment by Application

Adult Patients

Child Patients

Recombinant Human Coagulation Factor IX Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human Coagulation Factor IX market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Human Coagulation Factor IX and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human Coagulation Factor IX.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Human Coagulation Factor IX market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant Human Coagulation Factor IX manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Recombinant Human Coagulation Factor IX in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Recombinant Human Coagulation Factor IX in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Recombinant Human Coagulation Factor IX Industry Trends Table 2. Recombinant Human Coagulation Factor IX Industry Drivers Table 3. Recombinant Human Coagulation Factor IX Industry Opportunities and Challenges Table 4. Recombinant Human Coagulation Factor IX Industry Restraints Table 5. Global Recombinant Human Coagulation Factor IX Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Recombinant Human Coagulation Factor IX Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Recombinant Human Coagulation Factor IX Sales Market Share by Manufacturers Table 9. Global Recombinant Human Coagulation Factor IX Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Recombinant Human Coagulation Factor IX Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Recombinant Human Coagulation Factor IX Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Recombinant Human Coagulation Factor IX Manufacturers, Product Type & Application Table 13. Global Recombinant Human Coagulation Factor IX Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Human Coagulation Factor IX by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 500 IU/Bottle Table 17. Major Manufacturers of 250 IU/Bottle Table 18. Major Manufacturers of 2000 IU/Bottle Table 19. Major Manufacturers of 1000 IU/Bottle Table 20. Global Recombinant Human Coagulation Factor IX Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (k units) Table 22. Global Recombinant Human Coagulation Factor IX Sales by Type (2027-2032) & (k units) Table 23. Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026) Table 24. Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2027-2032) Table 25. Global Recombinant Human Coagulation Factor IX Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Recombinant Human Coagulation Factor IX Revenue by Type (2021-2026) & (k units) Table 27. Global Recombinant Human Coagulation Factor IX Revenue by Type (2027-2032) & (k units) Table 28. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2021-2026) Table 29. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Adult Patients Table 31. Major Manufacturers of Child Patients Table 32. Global Recombinant Human Coagulation Factor IX Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Recombinant Human Coagulation Factor IX Sales by Application (2021-2026) & (k units) Table 34. Global Recombinant Human Coagulation Factor IX Sales by Application (2027-2032) & (k units) Table 35. Global Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2026) Table 36. Global Recombinant Human Coagulation Factor IX Sales Market Share by Application (2027-2032) Table 37. Global Recombinant Human Coagulation Factor IX Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Recombinant Human Coagulation Factor IX Revenue by Application (2021-2026) & (k units) Table 39. Global Recombinant Human Coagulation Factor IX Revenue by Application (2027-2032) & (k units) Table 40. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application (2021-2026) Table 41. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application (2027-2032) Table 42. Global Recombinant Human Coagulation Factor IX Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Recombinant Human Coagulation Factor IX Sales by Region (2021-2026) & (k units) Table 44. Global Recombinant Human Coagulation Factor IX Sales Market Share by Region (2021-2026) Table 45. Global Recombinant Human Coagulation Factor IX Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Recombinant Human Coagulation Factor IX Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Recombinant Human Coagulation Factor IX Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (k units) Table 49. North America Recombinant Human Coagulation Factor IX Sales by Country (2027-2032) & (k units) Table 50. Europe Recombinant Human Coagulation Factor IX Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (k units) Table 52. Europe Recombinant Human Coagulation Factor IX Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Recombinant Human Coagulation Factor IX Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Recombinant Human Coagulation Factor IX Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Recombinant Human Coagulation Factor IX Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Recombinant Human Coagulation Factor IX Sales by Country (2027-2032) & (k units) Table 59. Global Recombinant Human Coagulation Factor IX Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Recombinant Human Coagulation Factor IX Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Recombinant Human Coagulation Factor IX Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Region (2021-2026) Table 63. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Region (2027-2032) Table 64. Bio-Techne Company Information Table 65. Bio-Techne Business Overview Table 66. Bio-Techne Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolio Table 68. Bio-Techne Recent Development Table 69. Cayman Company Information Table 70. Cayman Business Overview Table 71. Cayman Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Cayman Recombinant Human Coagulation Factor IX Product Portfolio Table 73. Cayman Recent Development Table 74. Cusabio Company Information Table 75. Cusabio Business Overview Table 76. Cusabio Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Cusabio Recombinant Human Coagulation Factor IX Product Portfolio Table 78. Cusabio Recent Development Table 79. Grifols Company Information Table 80. Grifols Business Overview Table 81. Grifols Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Grifols Recombinant Human Coagulation Factor IX Product Portfolio Table 83. Grifols Recent Development Table 84. IDELVION Company Information Table 85. IDELVION Business Overview Table 86. IDELVION Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. IDELVION Recombinant Human Coagulation Factor IX Product Portfolio Table 88. IDELVION Recent Development Table 89. NovoPro Bioscience Company Information Table 90. NovoPro Bioscience Business Overview Table 91. NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolio Table 93. NovoPro Bioscience Recent Development Table 94. Octapharma Company Information Table 95. Octapharma Business Overview Table 96. Octapharma Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Octapharma Recombinant Human Coagulation Factor IX Product Portfolio Table 98. Octapharma Recent Development Table 99. Sino Biological Company Information Table 100. Sino Biological Business Overview Table 101. Sino Biological Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Sino Biological Recombinant Human Coagulation Factor IX Product Portfolio Table 103. Sino Biological Recent Development Table 104. Baxter Company Information Table 105. Baxter Business Overview Table 106. Baxter Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Baxter Recombinant Human Coagulation Factor IX Product Portfolio Table 108. Baxter Recent Development Table 109. Biogen Company Information Table 110. Biogen Business Overview Table 111. Biogen Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Biogen Recombinant Human Coagulation Factor IX Product Portfolio Table 113. Biogen Recent Development Table 114. Diagbio Company Information Table 115. Diagbio Business Overview Table 116. Diagbio Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Diagbio Recombinant Human Coagulation Factor IX Product Portfolio Table 118. Diagbio Recent Development Table 119. Hualan Bio Company Information Table 120. Hualan Bio Business Overview Table 121. Hualan Bio Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolio Table 123. Hualan Bio Recent Development Table 124. Sanofi Company Information Table 125. Sanofi Business Overview Table 126. Sanofi Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Sanofi Recombinant Human Coagulation Factor IX Product Portfolio Table 128. Sanofi Recent Development Table 129. ChinaBiologic Company Information Table 130. ChinaBiologic Business Overview Table 131. ChinaBiologic Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolio Table 133. ChinaBiologic Recent Development Table 134. Shuyang Company Information Table 135. Shuyang Business Overview Table 136. Shuyang Recombinant Human Coagulation Factor IX Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Shuyang Recombinant Human Coagulation Factor IX Product Portfolio Table 138. Shuyang Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Recombinant Human Coagulation Factor IX Distributors List Table 142. Recombinant Human Coagulation Factor IX Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Recombinant Human Coagulation Factor IX Product Image Figure 2. Global Recombinant Human Coagulation Factor IX Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Human Coagulation Factor IX Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Human Coagulation Factor IX Sales (2021-2032) & (k units) Figure 5. Global Recombinant Human Coagulation Factor IX Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Recombinant Human Coagulation Factor IX Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 500 IU/Bottle Image Figure 9. 250 IU/Bottle Image Figure 10. 2000 IU/Bottle Image Figure 11. 1000 IU/Bottle Image Figure 12. Global Recombinant Human Coagulation Factor IX Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Recombinant Human Coagulation Factor IX Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2032) Figure 15. Global Recombinant Human Coagulation Factor IX Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Recombinant Human Coagulation Factor IX Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2021-2032) Figure 18. Adult Patients Image Figure 19. Child Patients Image Figure 20. Global Recombinant Human Coagulation Factor IX Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Recombinant Human Coagulation Factor IX Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2032) Figure 23. Global Recombinant Human Coagulation Factor IX Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Recombinant Human Coagulation Factor IX Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application (2021-2032) Figure 26. North America Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2032) Figure 28. U.S. Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2032) Figure 33. Germany Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2032) Figure 40. China Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2032) Figure 48. Brazil Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Recombinant Human Coagulation Factor IX Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Recombinant Human Coagulation Factor IX Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Recombinant Human Coagulation Factor IX Revenue (2021-2032) & (US$ Million) Figure 59. North America Recombinant Human Coagulation Factor IX Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Recombinant Human Coagulation Factor IX Revenue (2021-2032) & (US$ Million) Figure 61. Europe Recombinant Human Coagulation Factor IX Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Recombinant Human Coagulation Factor IX Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Recombinant Human Coagulation Factor IX Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Recombinant Human Coagulation Factor IX Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Recombinant Human Coagulation Factor IX Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Recombinant Human Coagulation Factor IX Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Recombinant Human Coagulation Factor IX Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 500 IU/Bottle
  • 250 IU/Bottle
  • 2000 IU/Bottle
  • 1000 IU/Bottle
Applications
  • Adult Patients
  • Child Patients
Companies covered
  • Bio-Techne
  • Cayman
  • Cusabio
  • Grifols
  • IDELVION
  • NovoPro Bioscience
  • Octapharma
  • Sino Biological
  • Baxter
  • Biogen
  • Diagbio
  • Hualan Bio
  • Sanofi
  • ChinaBiologic
  • Shuyang

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Human Coagulation Factor IX Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Human Coagulation Factor IX Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Recombinant Human Coagulation Factor IX Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Recombinant Human Coagulation Factor IX Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Recombinant Human Coagulation Factor IX Market Dynamics
  1. 2.1 Recombinant Human Coagulation Factor IX Industry Trends
  2. 2.2 Recombinant Human Coagulation Factor IX Industry Drivers
  3. 2.3 Recombinant Human Coagulation Factor IX Industry Opportunities and Challenges
  4. 2.4 Recombinant Human Coagulation Factor IX Industry Restraints
3 Recombinant Human Coagulation Factor IX Market by Manufacturers
  1. 3.1 Global Recombinant Human Coagulation Factor IX Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Recombinant Human Coagulation Factor IX Sales by Manufacturers (2021-2026)
  3. 3.3 Global Recombinant Human Coagulation Factor IX Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Recombinant Human Coagulation Factor IX Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant Human Coagulation Factor IX Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Recombinant Human Coagulation Factor IX Manufacturers, Product Type & Application
  7. 3.7 Global Recombinant Human Coagulation Factor IX Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant Human Coagulation Factor IX Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant Human Coagulation Factor IX Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant Human Coagulation Factor IX Tier 1, Tier 2, and Tier 3
4 Recombinant Human Coagulation Factor IX Market by Type
  1. 4.1 Recombinant Human Coagulation Factor IX Type Introduction
  2. 4.1.1 500 IU/Bottle
  3. 4.1.2 250 IU/Bottle
  4. 4.1.3 2000 IU/Bottle
  5. 4.1.4 1000 IU/Bottle
  6. 4.2 Global Recombinant Human Coagulation Factor IX Sales by Type
  7. 4.2.1 Global Recombinant Human Coagulation Factor IX Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Recombinant Human Coagulation Factor IX Sales by Type (2021-2032)
  9. 4.2.3 Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2032)
  10. 4.3 Global Recombinant Human Coagulation Factor IX Revenue by Type
  11. 4.3.1 Global Recombinant Human Coagulation Factor IX Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Recombinant Human Coagulation Factor IX Revenue by Type (2021-2032)
  13. 4.3.3 Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2021-2032)
5 Recombinant Human Coagulation Factor IX Market by Application
  1. 5.1 Recombinant Human Coagulation Factor IX Application Introduction
  2. 5.1.1 Adult Patients
  3. 5.1.2 Child Patients
  4. 5.2 Global Recombinant Human Coagulation Factor IX Sales by Application
  5. 5.2.1 Global Recombinant Human Coagulation Factor IX Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Recombinant Human Coagulation Factor IX Sales by Application (2021-2032)
  7. 5.2.3 Global Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2032)
  8. 5.3 Global Recombinant Human Coagulation Factor IX Revenue by Application
  9. 5.3.1 Global Recombinant Human Coagulation Factor IX Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Recombinant Human Coagulation Factor IX Revenue by Application (2021-2032)
  11. 5.3.3 Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application (2021-2032)
6 Global Recombinant Human Coagulation Factor IX Sales by Region
  1. 6.1 Global Recombinant Human Coagulation Factor IX Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Human Coagulation Factor IX Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Human Coagulation Factor IX Sales by Region (2021-2026)
  4. 6.2.2 Global Recombinant Human Coagulation Factor IX Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Human Coagulation Factor IX Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Recombinant Human Coagulation Factor IX Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Recombinant Human Coagulation Factor IX Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Recombinant Human Coagulation Factor IX Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Recombinant Human Coagulation Factor IX Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Recombinant Human Coagulation Factor IX Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Recombinant Human Coagulation Factor IX Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Recombinant Human Coagulation Factor IX Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Recombinant Human Coagulation Factor IX Revenue by Region
  1. 7.1 Global Recombinant Human Coagulation Factor IX Revenue by Region
  2. 7.1.1 Global Recombinant Human Coagulation Factor IX Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Recombinant Human Coagulation Factor IX Revenue by Region (2021-2026)
  4. 7.1.3 Global Recombinant Human Coagulation Factor IX Revenue by Region (2027-2032)
  5. 7.1.4 Global Recombinant Human Coagulation Factor IX Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Recombinant Human Coagulation Factor IX Revenue (2021-2032)
  8. 7.2.2 North America Recombinant Human Coagulation Factor IX Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Recombinant Human Coagulation Factor IX Revenue (2021-2032)
  11. 7.3.2 Europe Recombinant Human Coagulation Factor IX Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Recombinant Human Coagulation Factor IX Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Recombinant Human Coagulation Factor IX Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Recombinant Human Coagulation Factor IX Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Recombinant Human Coagulation Factor IX Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bio-Techne
  2. 8.1.1 Bio-Techne Company Information
  3. 8.1.2 Bio-Techne Business Overview
  4. 8.1.3 Bio-Techne Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolio
  6. 8.1.5 Bio-Techne Recent Developments
  7. 8.2 Cayman
  8. 8.2.1 Cayman Company Information
  9. 8.2.2 Cayman Business Overview
  10. 8.2.3 Cayman Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cayman Recombinant Human Coagulation Factor IX Product Portfolio
  12. 8.2.5 Cayman Recent Developments
  13. 8.3 Cusabio
  14. 8.3.1 Cusabio Company Information
  15. 8.3.2 Cusabio Business Overview
  16. 8.3.3 Cusabio Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cusabio Recombinant Human Coagulation Factor IX Product Portfolio
  18. 8.3.5 Cusabio Recent Developments
  19. 8.4 Grifols
  20. 8.4.1 Grifols Company Information
  21. 8.4.2 Grifols Business Overview
  22. 8.4.3 Grifols Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Grifols Recombinant Human Coagulation Factor IX Product Portfolio
  24. 8.4.5 Grifols Recent Developments
  25. 8.5 IDELVION
  26. 8.5.1 IDELVION Company Information
  27. 8.5.2 IDELVION Business Overview
  28. 8.5.3 IDELVION Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 IDELVION Recombinant Human Coagulation Factor IX Product Portfolio
  30. 8.5.5 IDELVION Recent Developments
  31. 8.6 NovoPro Bioscience
  32. 8.6.1 NovoPro Bioscience Company Information
  33. 8.6.2 NovoPro Bioscience Business Overview
  34. 8.6.3 NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolio
  36. 8.6.5 NovoPro Bioscience Recent Developments
  37. 8.7 Octapharma
  38. 8.7.1 Octapharma Company Information
  39. 8.7.2 Octapharma Business Overview
  40. 8.7.3 Octapharma Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Octapharma Recombinant Human Coagulation Factor IX Product Portfolio
  42. 8.7.5 Octapharma Recent Developments
  43. 8.8 Sino Biological
  44. 8.8.1 Sino Biological Company Information
  45. 8.8.2 Sino Biological Business Overview
  46. 8.8.3 Sino Biological Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sino Biological Recombinant Human Coagulation Factor IX Product Portfolio
  48. 8.8.5 Sino Biological Recent Developments
  49. 8.9 Baxter
  50. 8.9.1 Baxter Company Information
  51. 8.9.2 Baxter Business Overview
  52. 8.9.3 Baxter Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Baxter Recombinant Human Coagulation Factor IX Product Portfolio
  54. 8.9.5 Baxter Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Recombinant Human Coagulation Factor IX Product Portfolio
  60. 8.10.5 Biogen Recent Developments
  61. 8.11 Diagbio
  62. 8.11.1 Diagbio Company Information
  63. 8.11.2 Diagbio Business Overview
  64. 8.11.3 Diagbio Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Diagbio Recombinant Human Coagulation Factor IX Product Portfolio
  66. 8.11.5 Diagbio Recent Developments
  67. 8.12 Hualan Bio
  68. 8.12.1 Hualan Bio Company Information
  69. 8.12.2 Hualan Bio Business Overview
  70. 8.12.3 Hualan Bio Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolio
  72. 8.12.5 Hualan Bio Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi Recombinant Human Coagulation Factor IX Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
  79. 8.14 ChinaBiologic
  80. 8.14.1 ChinaBiologic Company Information
  81. 8.14.2 ChinaBiologic Business Overview
  82. 8.14.3 ChinaBiologic Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolio
  84. 8.14.5 ChinaBiologic Recent Developments
  85. 8.15 Shuyang
  86. 8.15.1 Shuyang Company Information
  87. 8.15.2 Shuyang Business Overview
  88. 8.15.3 Shuyang Recombinant Human Coagulation Factor IX Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Shuyang Recombinant Human Coagulation Factor IX Product Portfolio
  90. 8.15.5 Shuyang Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Human Coagulation Factor IX Value Chain Analysis
  2. 9.1.1 Recombinant Human Coagulation Factor IX Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Human Coagulation Factor IX Production Mode & Process
  6. 9.2 Recombinant Human Coagulation Factor IX Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Human Coagulation Factor IX Distributors
  9. 9.2.3 Recombinant Human Coagulation Factor IX Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst